More women had interstitial cystitis/bladder pain syndrome and more men had ... POST VASECTOMY SEMEN ANALYSIS: DOES PATIENT. CONVENIENCE ...
THE JOURNAL OF UROLOGYâ
e504
MP37-18 EVALUATING PATTERNS OF TESTOSTERONE PRESCRIPTION AMONG 40,878 USERS IN BRITISH COLUMBIA BETWEEN 1997-2013 Jennifer Locke*, Ryan Flannigan, Hao Luo, Mahyar Etminan, Ted Hoyda, S. Larry Goldenberg, Vancouver, Canada INTRODUCTION AND OBJECTIVES: Testosterone therapy (TRT) is FDA approved for symptomatic primary or secondary hypogonadism. However, an increase in off-label TRT supplementation is occurring in men despite lack of efficacy and safety data. Furthermore, the associations between TRT and comorbid diseases such as cardiovascular disease, diabetes and prostate cancer (CaP), have not been well characterized in this population. METHODS: All prescriptions for TRT between 1997 and 2013 were identified from the longitudinal British Columbian (pharmacy) PharmaNet database. Descriptive statistics were used to examine demographic and utilization information of men with TRT prescriptions using the longitudinal inpatient (discharge abstract database) DAD and outpatient (medical services plan) MSP databases. This was completed in accordance with UBC ethics protocols. RESULTS: 40,878 patients prescribed TRT within the study period of 16 years were evaluated. The majority of TRT were prescribed by general practitioners (92.0%) with few prescriptions by urologists (7.6%), internists (4.7%) and endocrinologists (4.1%),. The number of prescriptions per year increased 7-fold over the 16-year period, specifically in men aged 51-61 (from 2,205 to 16,066) and 61-71 (from 2,025 to 14,541). 74% of men received more than one TRT prescription and most (76%) changed the route of TRT administration over the course of their treatment. Injections were the most common route of administration, followed by capsules, then gels. The mean duration of TRT use was 518 days (SD +/- 821 days). Men prescribed TRTs had a baseline prevalence of CaP in 1.1%, diabetes in 36.9%, myocardial infarctions in 9.9%, and arterial embolism or thrombosis in 0.2% of men. CONCLUSIONS: We have characterized the longitudinal TRT patterns in a population of 40,878 TRT users. Despite the lack of efficacy and safety data there were annual increases in the prescription numbers. The most popular route of administration was injections. TRT use occurred in many men with baseline cardiovascular disease and CaP. Future work will aim to investigate TRT use in relation to pre, intra, and post-treatment serum TRT levels, cardiovascular events, diabetes and prostate diagnoses. Source of Funding: none
MP37-19 DOES SEX MATTER? A MATCHED PAIRS ANALYSIS OF NEUROMODULATION OUTCOMES IN WOMEN AND MEN Priyanka Gupta*, Natalie Gaines, Jason Gilleran, Kim A. Killinger, Jamie Bartley, Cheryl Wolfert, Judith A. Boura, Kenneth M. Peters, Royal Oak, MI INTRODUCTION AND OBJECTIVES: There is a lack of understanding regarding differences in response to neuromodulation between women and men. We aim to evaluate whether baseline symptoms and outcomes are influenced by sex in a matched cohort. METHODS: Patients in our prospective database that had a tined lead placed were reviewed. Those that had initial success and subsequent implantable pulse generator (IPG) were matched on age and urologic diagnosis. History, voiding diaries, Interstitial Cystitis Symptom/ Problem Index (ICSIPI) and Overactive Bladder symptom severity (OABq ss)/health related quality of life (HRQOL) at baseline, 3 and 6 months, and 1, 2, and 3 years were evaluated using descriptive statistics, repeated measures, and matched pair GEE or Mixed analyses. RESULTS: Of all 590 patients in the database, more women than men received an IPG (452/488; 92.6% vs. 84/102 men; 82.4%; p¼0.0011). More women had interstitial cystitis/bladder pain syndrome and more men had urgency/frequency (p
